Lite Strategy

Lite Strategy EBITDA Margin

The EBITDA Margin of Lite Strategy (LITS) as of Nov 20, 2026 is 22.27 %. In the previous year, EBITDA Margin was -75.31 % — a change of -129.57% (higher).

EBITDA Margin

22.27 %

YoY

-129.57%

Last updated:

EBITDA Margin of Lite Strategy is 2024 22.27 % . EBITDA Margin of Lite Strategy was 2023 -75.31 % . It decreases by -129.57% higher compared to the previous year.

The Lite Strategy EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2017
10.24 USD
Jan 1, 2018
-1,764.81 USD
Jan 1, 2019
-940.04 USD
Jan 1, 2020
-92.58 USD
Jan 1, 2021
-173.65 USD
Jan 1, 2022
-185.48 USD
Jan 1, 2023
-75.31 USD
Jan 1, 2024
22.27 USD
The Lite Strategy EBITDA Margin history
YEAREBITDA MarginYoY
22.27 %-129.57%
-75.31 %-59.40%
-185.48 %+6.81%
-173.65 %+87.57%
-92.58 %-90.15%
-940.04 %-46.73%
-1,764.81 %-17,340.31%
10.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

EBITDA Margin of Lite Strategy is 22.27 % in 2024.

EBITDA Margin of Lite Strategy changed from -75.31 % to 22.27 %, representing a -129.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Lite Strategy with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Lite Strategy

All Key Metrics — Lite Strategy